United States set
Menu Shopping cart $0 Search
Manufactured by BioVendor

Human Pepsinogen II ELISA

  • Regulatory status:RUO
  • Type:Sandwich ELISA, HRP-labelled antibody
  • Species:Human
Cat. No. Size Price

RIS008R 96 wells (1 kit) $726,75
PubMed Product Details
Technical Data


Sandwich ELISA, HRP-labelled antibody


The RIS008R Human Pepsinogen II ELISA Enzyme Linked ImmunoSorbent Assay (ELISA) for the measurement of human pepsinogen II levels in serum. It is intended for research use only. This ELISA (enzyme-linked immunosorbent assay) kit is intended for the quantitative determination of human pepsinogen II levels in serum. Determination of human serum pepsinogen II level would allow calculation of the ratio of pepsinogen I/II, which was reported to be a useful tool in the aid of diagnosing the functional states of acid secreting gastric mucosa.



Sample Requirements

50 µl/well


On blue ice packs. Upon receipt, store the product at the temperature recommended below.


Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

6.3–100 ng/ml

Limit of Detection

0.1 ng/ml


This assay measures human pepsinogen II without any cross-reaction to human pepsinogen I.



  • RUO
  • calibration range 6.3-100 ng/ml
  • limit of detection 0.1 ng/ml
  • for the measurement of human pepsinogen II levels in serum
  • controls

Research topic



Pepsinogen consists of a single polypeptide chain of 375 amino acids with an average molecular weight of 42 kDa. Pepsinogen I is synthesized at gastric chief cells and mucous neck cells, while pepsinogen II is produced not only by gastric chief cells and mucous neck cells, but also by clear mucous cells of antrum and Brunner’s glands in the proximal duodenum, etc. The clinical applications of measuring pepsinogen I and pepsinogen II are a useful aid in diagnosing severe atrophic gastritis and stomach cancer. It was suggested that the measurement of serum pepsinogens served as a “serological biopsy” for predicting the presence of atrophic gastritis or superficial gastritis. Atrophic Gastritis: It was found that serum pepsinogen I level falling to less than 20 ng/ml was highly specific for severe atrophic gastritis. It is also observed that serum pepsinogen I levels fell with increasing severity of mucosal damage in atrophic gastritis. The diagnostic sensitivity and specificity of serum pepsinogen I level for advanced atrophic corpus gastritis are about 92% and 90% respectively. On the other hand, the decrease in serum pepsinogen I levels in patients with pernicious anemia and atrophic gastritis was found to be associated with normal or raised pepsinogen II levels. Therefore, a pepsinogen I/pepsinogen II ratio is significantly lower than those with superficial gastritis or normal remnant mucosa. Stomach Cancer: Low serum pepsinogen I levels as well as low ratio of pepsinogen I/II were found in patients with gastric cancer, with a threefold higher incidence. Other studies have concluded that low serum pepsinogen I levels may identify persons at increased risk for intestinal types of stomach cancer. Duodenal Ulcer: A low serum pepsinogen I level can exclude a diagnosis of duodenal ulcer. Although a high pepsinogen I level has less clinical use for establishing the diagnosis of a duodenal ulcer, the combination of hypergastrinemia and a highly elevated serum pepsinogen I strongly suggests the possibility of the Zollinger-Ellison syndrome.

Summary References (14)

References to Pepsinogen

  • Fernandez R, Vizoso F, Rodriguez JC, Merino AM, Gonzalez LO, Quintela I, Andicoechea A, Truan N, Diez MC. Expression and prognostic significance of pepsinogen C in gastric carcinoma. Ann Surg Oncol. 2000 Aug;7 (7):508-14
  • Kalinovskii VP, Gamaiunova VB, Shumakov AP, Khanson KP. [Radioimmunoassay of serum pepsinogen I in chronic gastritis and stomach cancer]. Vopr Onkol. 2000;46 (2):153-5
  • Kitahara F, Kobayashi K, Sato T, Kojima Y, Araki T, Fujino MA. Accuracy of screening for gastric cancer using serum pepsinogen concentrations. Gut. 1999 May;44 (5):693-7
  • Korstanje A, den Hartog G, Biemond I, Lamers CB. The serological gastric biopsy: a non-endoscopical diagnostic approach in management of the dyspeptic patient: significance for primary care based on a survey of the literature. Scand J Gastroenterol Suppl. 2002; (236):22-6
  • Kuipers EJ. In through the out door: serology for atrophic gastritis. Eur J Gastroenterol Hepatol. 2003 Aug;15 (8):877-9
  • Miki K. [Serum pepsinogen I/II ratio test]. Nihon Rinsho. 2003 Jan;61 (1):92-5
  • Miki K, Morita M, Sasajima M, Hoshina R, Kanda E, Urita Y. Usefulness of gastric cancer screening using the serum pepsinogen test method. Am J Gastroenterol. 2003 Apr;98 (4):735-9
  • Samloff IM. Slow moving protease and the seven pepsinogens. Electrophoretic demontration of the existence of eight proteolytic fractions in human gastric mucosa. Gastroenterology. 1969 Dec;57 (6):659-69
  • Samloff IM, Taggart RT. Pepsinogens, pepsins, and peptic ulcer. Clin Invest Med. 1987 May;10 (3):215-21
  • Shumakov AR, Fedorov SN, Kalinovskii VP, Khanson KP. [Evaluation of pepsinogen A expression in stomach cancer]. Vopr Onkol. 1999;45 (3):238-40
  • Sipponen P, Harkonen M, Alanko A, Suovaniemi O. Diagnosis of atrophic gastritis from a serum sample. Clin Lab. 2002;48 (9-10):505-15
  • So JB, Yeoh KG, Moochala S, Chachlani N, Ho J, Wong WK, Mack P, Goh PM. Serum pepsinogen levels in gastric cancer patients and their relationship with Helicobacter pylori infection: a prospective study. Gastric Cancer. 2002;5 (4):228-32
  • Tabata H, Fuchigami T, Kobayashi H, Sakai Y, Nakanishi M, Tomioka K, Nakamura S, Matsumoto T, Fujishima M. Difference in degree of mucosal atrophy between elevated and depressed types of gastric epithelial tumors. Scand J Gastroenterol. 2001 Nov;36 (11):1134-40
  • Varis K, Sipponen P, Laxen F, Samloff IM, Huttunen JK, Taylor PR, Heinonen OP, Albanes D, Sande N, Virtamo J, Harkonen M. Implications of serum pepsinogen I in early endoscopic diagnosis of gastric cancer and dysplasia. Helsinki Gastritis Study Group. Scand J Gastroenterol. 2000 Sep;35 (9):950-6
Related Products Docs